HALO — HALOZYME THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1159036 ·
Last close
$95.97
Market Cap
$10.94B
52W High
$134.00
52W Low
$61.23
ADV30
2,321,087
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 492,974,000 | 410,499,000 | 294,969,000 | 247,049,000 | 3,473,346,000 | 1,029,988,000 | 3,528,585,000 |
| Jun 2026 | 480,999,000 | 401,828,000 | 287,654,000 | 229,913,000 | 2,577,408,000 | 163,138,000 | 2,433,865,000 |
| Mar 2026 | 376,708,000 | 297,470,000 | 184,517,000 | 150,049,000 | 2,672,719,000 | 309,749,000 | 2,453,083,000 |
| Dec 2025 | 451,767,000 | 372,997,000 | 240,696,000 | -141,591,000 | 2,525,323,000 | 133,820,000 | 2,476,509,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$818,595,000
Investing CF
$-605,719,000
Financing CF
$-110,751,000
CapEx
$-300,142,000
Dividends Paid
—
Buybacks
$-38,883,000
EPS Diluted TTM
$3.35
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$151,259,000
Inventory
$137,135,000
Receivables
$455,827,000
ST Investments
$67,865,000
EBIT TTM
$603,641,000
Pretax Income TTM
$583,338,000
Interest Exp TTM
$20,303,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,802,448,000
EBITDA
$1,143,614,976
Free Cash Flow
$411,703,488
Enterprise Value
$13,990,772,736
Total Cash
$1,074,386,944
Total Debt
$3,250,302,976
Shares Out
114,010,000
Trailing EPS
$4.00
Book Value
$-0.48
ROE
216.4%
ROA
22.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,396,611,000 | 802,593,000 | 316,889,000 | 2,525,323,000 | 2,476,509,000 | 48,814,000 | 651,558,000 |
| Dec 2024 | 1,015,324,000 | 551,475,000 | 444,091,000 | 2,063,477,000 | 1,699,656,000 | 363,821,000 | 479,064,000 |
| Dec 2023 | 829,253,000 | 337,574,000 | 281,594,000 | 1,733,270,000 | 1,649,462,000 | 83,808,000 | 388,571,000 |
| Dec 2022 | 660,116,000 | 267,531,000 | 202,129,000 | 1,841,511,000 | 1,671,713,000 | 169,798,000 | 240,110,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,663,738,000
NetIncome TTM
$413,596,000
OpCashFlow TTM
—
Assets (Latest)
$2,577,408,000
Forward EPS
$10.54
Max Pain — expiry 2026-12-18
max pain strike: $90.00 · spot: $95.80 · call oi: 4,599 · put oi: 3,145
Expected Move to 2026-12-18:
±$8.30
(8.66%) —
implied range
$87.50 –
$104.10
· ATM straddle on $95.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TECH | BIO-TECHNE Corp | $11.41B | $72.63 | — |
| KYMR | Kymera Therapeutics, Inc. | $10.37B | $121.52 | — |
| RGEN | REPLIGEN CORP | $10.30B | $162.18 | — |
| QGEN | QIAGEN N.V. | $10.27B | $49.75 | — |
| PCVX | Vaxcyte, Inc. | $9.40B | $59.40 | — |
News headlines (Yahoo Finance, 1h cache)
Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions
2026-11-12 12:13 · Yahoo
Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands
2026-11-12 11:12 · Yahoo
Can You Make Money Off Halozyme Stock Now?
2026-11-11 20:55 · Yahoo
Halozyme Therapeutics' Current Royalty Portfolio Expected to Peak in 2029, Morgan Stanley Says
2026-11-11 16:11 · Yahoo
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
2026-11-10 19:42 · Yahoo
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
2026-11-10 13:40 · Yahoo
HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update
2026-11-10 11:49 · Yahoo
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued
2026-11-06 17:15 · Yahoo
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance
2026-11-06 16:58 · Yahoo
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
2026-11-06 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.